Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Seeking Alpha
Company Participants Amy Parison - Senior VP & CFO Gilmore O'Neill Conference Call Participants Jasmine Fels - Barclays Bank PLC, Research Division Presentation Jasmine Fels Barclays Bank PLC, Research Division Okay. Hi, everyone. Good morning. Thank you for joining us. I'm Jasmine Fels. I'm one of the biotech analysts here at Barclays, and we're very happy to have Editas Medicine here with us today. So we have Gilmore O'Neill, who is the President and CEO; and Amy Parison, who is the CFO. So thank you, both, for joining us. Amy Parison Senior VP & CFO Thank you. Gilmore O'Neill Great to be with you. Question-and-Answer Session Jasmine Fels Barclays Bank PLC, Research Division Great. Okay. All right. Let's start with the basics. So can you give an overview of your platform and your approach to gene editing and how that's differentiated from others in the broader space? Gilmore O'Neill Yes, we're happy to. So Editas is an in vivo CRISPR therapeuti
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine (EDIT) was upgraded by JonesTrading from "hold" to "buy". They now have a $8.00 price target on the stock.MarketBeat
- Editas Medicine (EDIT) was given a new $6.00 price target by Robert W. Baird.MarketBeat
- Editas Medicine (EDIT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.MarketBeat
- Editas Medicine (EDIT) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates [Yahoo! Finance]Yahoo! Finance
EDIT
Earnings
- 3/9/26 - Beat
EDIT
Sec Filings
- 3/9/26 - Form 10-K
- 3/9/26 - Form 8-K
- 3/4/26 - Form 4
- EDIT's page on the SEC website